RAMUCIRUMAB

N/A

Manufactured by Eli Lilly and Company

9,650 FDA adverse event reports analyzed

Last updated: 2026-04-15

About RAMUCIRUMAB

RAMUCIRUMAB is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Eli Lilly and Company. The most commonly reported adverse reactions for RAMUCIRUMAB include MALIGNANT NEOPLASM PROGRESSION, DEATH, INTERSTITIAL LUNG DISEASE, FEBRILE NEUTROPENIA, NEUTROPENIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for RAMUCIRUMAB.

Top Adverse Reactions

MALIGNANT NEOPLASM PROGRESSION783 reports
DEATH561 reports
INTERSTITIAL LUNG DISEASE292 reports
FEBRILE NEUTROPENIA257 reports
NEUTROPENIA257 reports
DECREASED APPETITE224 reports
DIARRHOEA217 reports
OFF LABEL USE207 reports
FATIGUE197 reports
NAUSEA195 reports
DISEASE PROGRESSION189 reports
HYPERTENSION185 reports
PYREXIA184 reports
NEUTROPHIL COUNT DECREASED176 reports
ASCITES168 reports
NEUROPATHY PERIPHERAL168 reports
DRUG INEFFECTIVE160 reports
PNEUMONIA152 reports
ANAEMIA149 reports
PROTEINURIA138 reports
VOMITING126 reports
DYSPNOEA124 reports
MALAISE123 reports
ABDOMINAL PAIN121 reports
PLATELET COUNT DECREASED113 reports
THROMBOCYTOPENIA101 reports
EPISTAXIS96 reports
WHITE BLOOD CELL COUNT DECREASED96 reports
PERITONITIS93 reports
ASTHENIA89 reports
STOMATITIS89 reports
PNEUMONITIS88 reports
PLEURAL EFFUSION87 reports
GENERAL PHYSICAL HEALTH DETERIORATION86 reports
NEPHROTIC SYNDROME85 reports
SEPSIS83 reports
TUMOUR HAEMORRHAGE81 reports
PULMONARY EMBOLISM80 reports
WEIGHT DECREASED78 reports
RASH77 reports
GASTROINTESTINAL PERFORATION76 reports
HAEMOPTYSIS75 reports
MYELOSUPPRESSION71 reports
DISSEMINATED INTRAVASCULAR COAGULATION70 reports
GASTROINTESTINAL HAEMORRHAGE69 reports
HAEMOGLOBIN DECREASED68 reports
OEDEMA PERIPHERAL66 reports
OEDEMA62 reports
PRODUCT USE IN UNAPPROVED INDICATION61 reports
SEPTIC SHOCK61 reports
CARDIAC FAILURE60 reports
INFUSION RELATED REACTION60 reports
CONSTIPATION59 reports
ACUTE KIDNEY INJURY58 reports
DEEP VEIN THROMBOSIS58 reports
MUCOSAL INFLAMMATION56 reports
PRURITUS56 reports
THERAPY PARTIAL RESPONDER55 reports
ALOPECIA52 reports
GASTRIC PERFORATION52 reports
INFECTION52 reports
PAIN52 reports
ALANINE AMINOTRANSFERASE INCREASED51 reports
ERYTHEMA51 reports
HAEMORRHAGE51 reports
COUGH50 reports
ABDOMINAL PAIN UPPER49 reports
DEHYDRATION49 reports
HYPERSENSITIVITY46 reports
METASTASES TO LIVER46 reports
RESPIRATORY FAILURE46 reports
DYSPHAGIA44 reports
LEUKOPENIA43 reports
PALMAR PLANTAR ERYTHRODYSAESTHESIA SYNDROME43 reports
C REACTIVE PROTEIN INCREASED42 reports
HEPATIC FUNCTION ABNORMAL42 reports
PNEUMOTHORAX42 reports
CEREBRAL HAEMORRHAGE41 reports
FALL41 reports
HEADACHE41 reports
CHEST PAIN40 reports
NEOPLASM PROGRESSION40 reports
HYPOAESTHESIA39 reports
BACK PAIN37 reports
HYPOTENSION37 reports
HAEMATEMESIS36 reports
HEPATIC FAILURE36 reports
PNEUMONIA ASPIRATION36 reports
ANAPHYLACTIC REACTION35 reports
ASPARTATE AMINOTRANSFERASE INCREASED35 reports
CONDITION AGGRAVATED35 reports
HYPONATRAEMIA35 reports
RENAL IMPAIRMENT35 reports
THROMBOSIS35 reports
BLOOD PRESSURE INCREASED34 reports
THROMBOTIC MICROANGIOPATHY34 reports
HYPOTHYROIDISM33 reports
POLYNEUROPATHY33 reports
BONE MARROW FAILURE32 reports
URTICARIA31 reports

Report Outcomes

Out of 6,010 classified reports for RAMUCIRUMAB:

Serious 93.8%Non-Serious 6.2%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Male3,451 (66.6%)
Female1,729 (33.4%)

Reports by Age

Age 65306 reports
Age 75270 reports
Age 70175 reports
Age 68165 reports
Age 66155 reports
Age 67153 reports
Age 69140 reports
Age 60135 reports
Age 74134 reports
Age 72133 reports
Age 64124 reports
Age 73123 reports
Age 71122 reports
Age 61119 reports
Age 76113 reports
Age 77107 reports
Age 62103 reports
Age 55100 reports
Age 5995 reports
Age 5894 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with RAMUCIRUMAB?

This profile reflects 9,650 FDA FAERS reports that mention RAMUCIRUMAB. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for RAMUCIRUMAB?

Frequently reported terms in FAERS include MALIGNANT NEOPLASM PROGRESSION, DEATH, INTERSTITIAL LUNG DISEASE, FEBRILE NEUTROPENIA, NEUTROPENIA, DECREASED APPETITE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures RAMUCIRUMAB?

Labeling and FAERS entries often list Eli Lilly and Company in connection with RAMUCIRUMAB. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.